SeqLL Provides First Quarter 2022 Financial Results and a Corporate Update
BILLERICA, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company...
Year: 2022
Ocuphire Pharma Announces Financial Results for First Quarter 2022 and Provides Corporate Update
Nyxol Posts 5 Positive Clinical Data Readouts Including Presbyopia in Last 12 Months Successfully Enrolled 4 Late-Stage Trials for Nyxol...
MEDIROM Healthcare Technologies Inc. Announces Preliminary 2021 Financial Results
Revenue growth of 62% / Total Gross Margin 26.4%NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc....
Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA
MILAN, Italy and NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering...
Vitalhub Corp to Present at the Roth Canada Showcase Day
TORONTO, May 13, 2022 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) today announces that will be...
Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products
Statera expects to acquire option to license Lay Sciences products for respiratory & gastrointestinal disordersFORT COLLINS, Colo., May 13, 2022...
LifeMD, Inc. Reports First Quarter 2022 Results
First quarter 2022 consolidated revenue of $29.0 million up 60% from the same year ago period.Adjusted EPS of $(0.25), 14%...
InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update
Expands rare cannabinoid portfolio with the addition of CBT and CBDVStrengthens IP with publication of a patent application for novel...
BridgeBio Pharma Sells Rare Pediatric Disease Priority Review Voucher for $110 Million and Defers Principal Payment on Senior Debt by Two Years
-Entered into a definitive agreement to sell the rare pediatric disease Priority Review Voucher (PRV) it obtained in February 2021...
Spectral Announces First Quarter Results and Provides Corporate Update
TORONTO, May 13, 2022 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic...
Cognition Therapeutics to Participate in H.C. Wainwright Global Investment Conference
PURCHASE, N.Y., May 13, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing therapies that treat...
Abeona Therapeutics Reports First Quarter 2022 Financial Results
Disposition of MPS programs to reduce operating expenses and extend projected cash runway into 2Q 2023 Focus R&D resources on EB-101...
HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlights
MIRAMAR, Fla., May 13, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a biopharmaceutical...
Nabriva Therapeutics to Present at the H.C. Wainwright Global Investment Conference
DUBLIN, Ireland, May 13, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization...
Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022
BOSTON, May 13, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy...
Iterum Therapeutics Reports First Quarter 2022 Financial Results
-General Alignment with FDA on Key Aspects of Design of Proposed Additional Clinical Trial- -Cash Runway into 2024- DUBLIN, Ireland and...
ProMIS Neurosciences Announces First Quarter 2022 Results
TORONTO, Ontario and CAMBRIDGE, Massachusetts, May 13, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or...
Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update
FDA approval for EPSOLAY® (benzoyl peroxide, cream, 5%) represents Sol-Gel’s second approved product within less than a year; EPSOLAY is...
Humacyte First Quarter 2022 Financial Results and Business Update
-- Human Acellular Vessels™ (HAVs™) shipped to six hospitals in Ukraine for treatment of civilian and military vascular trauma injuries...
ProMIS Holds Annual and Special Meeting of Shareholders All Resolutions Approved
TORONTO, Ontario and CAMBRIDGE, Massachusetts, May 13, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or...
